2016-03-24 16:00Dividend Policy - The company plans to distribute a cash dividend of RMB 5 per 10 shares, totaling RMB 198,444,773.50[4]. - No stock bonus or capital reserve conversion to share capital will be implemented this year[5]. - The total distributable profit for the fiscal year 2015 was RMB 745,885,809.84, with the cash dividend representing 100% of the profit distribution[121]. - The cash dividend policy is compliant with the company's articles of association and has been transparently communicated to shareholders[121]. - The company has ensured that minority shareholders have had ample opportunity to express their opinions and that their legal rights have been adequately protected[121]. - The decision-making process regarding the cash dividend policy is complete and has involved independent directors fulfilling their responsibilities[121]. - The company has maintained a consistent cash dividend distribution strategy over the past three years, reflecting a commitment to returning value to shareholders[120][121]. - The cash dividends for the past three years have shown a significant commitment to shareholder returns, with varying percentages of net profit allocated to dividends[120]. Financial Performance - The company's operating revenue for 2015 was CNY 6,620,516,536.73, representing a 19.41% increase compared to CNY 5,544,233,777.86 in 2014[23]. - The net profit attributable to shareholders for 2015 was CNY 622,641,033.06, a 20.67% increase from CNY 515,978,431.82 in 2014[23]. - The net cash flow from operating activities increased by 29.33% to CNY 927,788,460.32 in 2015, up from CNY 717,393,893.55 in 2014[23]. - The basic earnings per share for 2015 was CNY 1.62, reflecting a 20.90% increase from CNY 1.34 in 2014[23]. - Total assets at the end of 2015 reached CNY 8,077,537,790.41, a 10.61% increase from CNY 7,302,605,055.90 at the end of 2014[23]. - The company's net assets attributable to shareholders increased by 17.58% to CNY 4,346,255,331.26 at the end of 2015, compared to CNY 3,696,516,567.53 at the end of 2014[23]. - The company reported a total of CNY 114,939,873.70 in non-recurring gains and losses for 2015, compared to CNY 66,019,361.36 in 2014[29]. Business Operations - The company has not changed its main business since its listing[20]. - The company’s board of directors has confirmed the accuracy and completeness of the annual report[3]. - The annual report includes forward-looking statements regarding future plans and risks[6]. - The company’s registered address is located at 38 Chuangye North Road, Jinwan District, Zhuhai City, Guangdong Province[16]. - The company’s A shares are listed on the Shenzhen Stock Exchange, while H shares are listed on the Hong Kong Stock Exchange[16]. - The company has maintained the same controlling shareholder for the past ten years[20]. - The accounting firm engaged by the company is Ruihua Certified Public Accountants[21]. - The company’s financial report is available on designated websites for public disclosure[19]. Research and Development - The company maintains a diversified product structure, focusing on various segments within the pharmaceutical industry, including oncology and reproductive health[35]. - In 2015, the company initiated 29 preclinical research projects in chemical and traditional Chinese medicine formulations, with 6 projects submitted for clinical trials[42]. - The company’s focus on R&D led to 8 new drugs in the pipeline in the biopharmaceutical sector, with 1 in clinical research and 3 submitted for clinical trials[42]. - The company plans to invest a total of RMB 600 million in the "Therapeutic Antibody Drug R&D and Industrialization Project" through a non-public issuance of A-shares, with RMB 306 million contributed by the company[151]. - The company is committed to increasing R&D investment to adapt to industry changes and maintain competitive advantages[101]. Market and Sales - The company’s marketing network includes over 4,000 personnel, optimizing resource allocation and expanding market scale[40]. - The revenue from the gastrointestinal segment increased by 31.21% to CNY 565.56 million, while the cardiovascular segment saw a decrease of 3.08% to CNY 151.94 million[49]. - Domestic sales accounted for 90.26% of total revenue at CNY 5.88 billion, with a year-on-year growth of 18.13%[51]. - The company’s overseas formulation sales exceeded RMB 13.5 million, with multiple product registrations obtained in the Philippines[41]. Investments and Subsidiaries - The company established a new subsidiary, Lian Hong Kong Co., Ltd., in January 2015, expanding its consolidation scope[57]. - The company successfully invested in Cynvenio, a US tumor gene sequencing company, and signed a framework agreement to establish a joint venture in China[46]. - The company established a new subsidiary, Youbao Technology, with a registered capital of RMB 10 million, in which the company holds a 30% stake[156]. Corporate Governance - The company has maintained a governance structure that ensures timely and accurate disclosure of major events and financial performance to shareholders[176]. - The company confirmed that there were no penalties or rectification issues during the reporting period[134]. - The company’s controlling shareholder and actual controller have maintained a good integrity status, with no significant debts overdue[135]. Related Party Transactions - The total amount of related party transactions for the reporting period was 344.68 million yuan, with 298.83 million yuan involving transactions with the controlling shareholder[144]. - The company has engaged in various related party transactions primarily for daily operational needs, which do not significantly affect its financial outcomes[150]. - The company has no significant impact on its financial results or financial position from related party transactions[150]. Environmental and Social Responsibility - The company has established a comprehensive environmental emergency response plan and has passed ISO14001 environmental management system certification[179]. - The company has not experienced any major environmental pollution incidents during the reporting period[179]. - The company has committed to improving employee working conditions and safety, adhering to labor laws and regulations[178].